ArticlePloS one2026
Artificial intelligence-detected HER2 strong-positive tumor proportion predicts FISH positivity and treatment response in breast cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have revolutionized breast cancer treatment, necessitating standardized HER2 testing. However, current immunochemistry-based HER2 assessment faces challenges due to subjectivity and variability among observers, prompting the guidance of artificial intelligence (AI). We evaluated AI's efficacy in HER2 status assessment and treatment response prediction, especially focusing on complete and intense circumferential HER2-positive (3+) tumor cells. An AI-powered HER2 analyzer (Lunit SCOPE HER2, Lunit Inc., Seoul, South Korea) and three pathologists independently assessed HER2 3 + tumor cell proportions from whole-slide images of 191 breast cancer cases from Kyung Hee University Hospital. Logistic regression and receiver operating characteristic (ROC) curves determined predictive accuracy. AI-detected 3 + tumor cell proportions strongly correlated with fluorescent in situ hybridization (FISH) positivity (area under ROC curve [AUC]: 0.783) and pathological complete response (pCR) rates (odds ratio [OR]: 1.003-1.052), outperforming pathologists' assessments. Combining AI improved prediction accuracy of pathologists, with an AUC increased from 0.712-0.813 to 0.790-0.821 for predicting FISH positivity and median OR increased from 0.996-1.061 to 1.003-1.055 for predicting pCR. Overall, this preliminary study suggests that AI could enhance HER2 status determination and treatment response prediction, complementing traditional pathological evaluation of HER2 immunohistochemistry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.